Effects of disease activity on anti-Saccharomyces cerevisiae antibodies: Implications for diagnosis and follow-up of children with Crohn's disease

Inflammatory Bowel Diseases

Volumn 10, Issue 3, 2004, Pages 234-239

  Canani, Roberto Berni ^a   Romano, Maria Teresa ^a   Greco, Luigi ^a   Terrin, Gianluca ^a   Sferlazzas, Concetta ^b   Barabino, Arrigo ^c   Fontanas, Massimo ^d   Roggero, Paola ^e   Guariso, Graziella ^f   De Angelis, GianLuigi ^g   Fecarotta, Simona ^a   Polito, Gaetano ^a   Cucchiara, Salvatore ^h  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d V BUZZI CHILDREN S HOSPITAL   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY OF PARMA   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti Saccharomyces cerevisiae antibody; Children; Crohn's disease; Disease activity; Inflammatory bowel disease

Indexed keywords

AZATHIOPRINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MESALAZINE; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE;

ANTIBODY TITER; ARTICLE; CHILD; COLITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE SEVERITY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MEASUREMENT; PRIORITY JOURNAL; REMISSION; SACCHAROMYCES CEREVISIAE; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SEROLOGY; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANTIBODIES, FUNGAL; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INFANT; INFLAMMATORY BOWEL DISEASES; MALE; SACCHAROMYCES CEREVISIAE; SENSITIVITY AND SPECIFICITY;

EID: 2442505912     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200405000-00009     Document Type: Article

References (25)

1. Oliva-Hemcker M, Fiocchi C. Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. Inflamm Bowel Dis. 2002;8:112-128.
2. Jenkins HR. Inflammatory bowel disease. Arch Dis Child. 2001;85:435-437.
3. Hyams JS. Extraintestinal manifesta6tions of inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr. 1994;19:7-21.
4. Dubinsky MC, Ofman J, Urman M, et al. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol. 2001;96:758-765.
5. Dubinsky MC, Seidman EG. Diagnostic markers of inflammatory bowel disease. Curr Opin Gastroenterol. 2000;16:337-342.
6. Tibble J, Smale S, Bjarnson I. Value of intestinal function tests in inflammatory bowel disease. Inflammatory Bowel Disease Monitor. 2000;1:99-103.
7. Abreu MT. Serologic tests are helpful in managing inflammatory bowel disease. Inflamm Bowel Dis. 2002;8:224-226.
8. Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am. 1999;28:445-458.
9. Hyams JS. Crohn's disease. Pediatric Clin. North Am. 1996;43:255-277.
10. Griffiths AM, Buller HB. Inflammatory Bowel Disease. In: Walker WA, Durie PR, Hamilton JR, Walker Smith JA, Watkins JB, eds. Pediatric Gastrointestinal Disease. 3rd ed. Hamilton, Ontario Canada: BC Decker Inc., 2000:613-652.
11. Hoffenberg EJ, Fidanza S, Sauaia A. Serologic testing for inflammatory bowel disease. J Pediatr. 1999;134:447-451.
12. Nielsen O, Vainer B, Madsen S, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000;95:359-367.
13. Vermeire S, Joossens S, Peeters M. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology. 2001;120:827-833.
14. Papadakis KA, Targan SR. Current theories on the causes of inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28:283-296.
15. Annese V, Andreoli A, Andriulli A, et al. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis. A GISC Study. Am J Gastroenterol. 2001;96:2407-2412.
16. Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115:822-829.
17. Chong SKF. Blackshaw A J, Boyle S, et al. Histological diagnosis of chronic inflammatory bowel disease in childhood. Gut. 1985;26:55-59.
18. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a Pediatric Crohn's Disease Activity Index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
19. Rachmilevitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J. 1989;298:82-86.
20. Sandborn WJ, Loftus EV, Colombel JF, et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 2001;7:192-201.
21. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology. 2001;120:622-635.
22. Quinton JF, Sendid B, Reumax D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42:788-791.
23. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22.
24. Berni Canani R, Cirillo P, Bruzzese E. et al. Nitric oxide production in rectal dialysate is a marker of disease activity and location in children with inflammatory bowel disease. Am J Gastroenterol. 2002;97:1574-1576.
25. Abreu MT, Yang H. Defining subtypes of Crohn's disease patients. J Clin Gastroenterol. 2003;36:3-7.